Monographie - Ceftobiprole medocaril sodium

Poslední aktualizace :
16/12/2025

Ceftobiprole medocaril sodium

Chemický vzorec

Obchodní název

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Adaluzis	Irsko
Mabelio	Francie
Zevtera	äpanÏlsko, Finsko, Mexiko, NÏmecko, Norsko, Peru, Švédsko, Švýcarsko, Velká Británie

Odkazy : Ceftobiprole medocaril sodium

	typ	uveřejnění
2269	noviny	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3520	Laboratoř	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratoř	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratoř	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoř	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
4650	Laboratoř	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
5098	noviny	Esteban‑Cartelle B, Anaya B.J, Menéndez‑Conde C.P, Vicente‑Oliveros N , Serrano D.R, Álvarez‑Díaz A. Stability of Ceftobiprole Medocaril in Portable Elastomeric Infusion Devices. Infect Dis Ther 2025 ; 14:1685–1696.

Mentions Légales